

In the Claims

1-69 (canceled).

70 (new). An isolated monoclonal antibody or a fragment thereof that binds at least two different human inhibitory KIR receptor gene products, wherein said antibody or fragment thereof is capable of neutralizing KIR-mediated inhibition of NK cell cytotoxicity in NK cells expressing at least one of said two different human inhibitory KIR receptors, wherein said monoclonal antibody or fragment thereof is:

- a) the DF200 antibody produced by the hybridoma DF200, deposited as CNCM I-3224;
- b) a chimeric antibody comprising the variable region binding domains of the DF200 antibody;
- c) a humanized antibody comprising the CDRs of the DF200 antibody; or
- d) an Fab, Fab', Fab'-SH or F(ab')₂ fragment of any one of the antibodies set forth in a, b or c.

71 (new). The isolated monoclonal antibody or a fragment thereof according to claim 70, wherein said antibody is the DF200 antibody produced by the hybridoma DF200, deposited as CNCM I-3224.

72 (new). The isolated monoclonal antibody or a fragment thereof according to claim 71, wherein said fragment is an Fab, Fab', Fab'-SH or F(ab')₂ fragment of the DF200 antibody.

73 (new). The isolated monoclonal antibody or a fragment thereof according to claim 70, wherein said antibody is a chimeric antibody comprising the variable region binding domains of the DF200 antibody.

74 (new). The isolated monoclonal antibody or a fragment thereof according to claim 73, wherein said fragment is an Fab, Fab', Fab'-SH or F(ab')₂ fragment of said chimeric antibody.

75 (new). The isolated monoclonal antibody or a fragment thereof according to claim 70, wherein said antibody is a humanized antibody comprising the CDRs of the DF200 antibody.

76 (new). The isolated monoclonal antibody or a fragment thereof according to claim 75, wherein said fragment is an Fab, Fab', Fab'-SH or F(ab')₂ fragment of said humanized antibody.

77 (new). The isolated monoclonal antibody or fragment thereof according to claim 70, wherein said monoclonal antibody or fragment thereof binds to KIR2DL1 and KIR2DL2/3.

78 (new). An isolated monoclonal antibody or fragment thereof according to claim 70 conjugated or covalently bound toxin, detectable moiety, or solid support.

79 (new). A composition comprising a monoclonal antibody or fragment thereof according to claim 70 and a pharmaceutically acceptable excipient.

80 (new). The composition according to claim 79, further comprising IL-2.